Clinical Trial Update: A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing evening dosing of Xalacom in glaucoma patients has completed, evaluating efficacy and safety in open-angle glaucoma and ocu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Xalacom (latanoprost/timolol)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED